Life Science REIT PLC Director Declaration (8110P)

TIDMLABS

RNS Number : 8110P

Life Science REIT PLC

11 October 2023

LEI 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Director Declaration

Claire Boyle, Chair and Non-Executive Director of Life Science REIT, has been appointed to the Board of Nippon Active Value Fund plc, a company listed on the London Stock Exchange, with effect from 10 October 2023. In addition, Claire Boyle has resigned from her appointment as an Independent Non-Executive Director of abrdn Japan Investment Trust plc with effect from 10 October 2023.

This disclosure is made in accordance with Listing Rule 9.6.14.

Enquiries:

 
 Link Company Matters Limited - Company 
  Secretary 
 labs_cosec@linkgroup.co.uk 
 
 Ironstone Asset Management - Investment 
  Adviser 
 Simon Farnsworth/ Joanna Waddingham          via Buchanan below 
 
 Panmure Gordon - Joint Corporate Broker      +44 20 7886 2500 
 Alex Collins / Tom Scrivens 
 
 Jefferies International Limited - Joint 
  Corporate Broker                            +44 20 7029 8000 
 Tom Yeadon / Andrew Morris / Oliver Nott 
 G10 Capital Limited - AIFM                   +44 20 7397 5450 
 Verity Morgan-Jones / Paul Cowland 
 
   Buchanan - Financial PR                      +44 20 7466 5000 
 Mark Court / Henry Wilson / Verity Parker 
 LifeSciencereit@buchanan.uk.com

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from a buoyant early-stage funding environment, driving demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk . To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/ .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNZZMMGGMLGFZM

(END) Dow Jones Newswires

October 11, 2023 06:32 ET (10:32 GMT)

Life Science Reit (LSE:LABS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024